• Explore /
  • Poster
  • / Efficacy outcomes and biomarker analysis from phase II trial of escalating doses of neoadjuvant atezolizumab in patients with muscle-invasive urothelial carcinoma ineligible for cisplatin-based chemotherapy.

Efficacy outcomes and biomarker analysis from phase II trial of escalating doses of neoadjuvant atezolizumab in patients with muscle-invasive urothelial carcinoma ineligible for cisplatin-based chemotherapy.

Abstract Poster

Authors

null

Vadim S Koshkin

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

Vadim S Koshkin , Tanya Jindal , Jun Yan He , Li Zhang , Celine N. Galang , Divya Natesan , Vipul Kumar , Xiaolin Zhu , Jonathan Chou , Rahul Raj Aggarwal , Eric J. Small , Maxwell Meng , Sima P. Porten , David Yoonsuk Oh , Lawrence Fong , Terence W. Friedlander

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02451423

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 602)

DOI

10.1200/JCO.2024.42.4_suppl.602

Abstract #

602

Poster Bd #

G8

Abstract Disclosures

Similar Posters

First Author: Vadim S Koshkin

First Author: Hongsik Kim

First Author: Nick Van Dijk

First Author: Chiara Mercinelli